AstraZeneca's CEO reviews Japan ops
AstraZeneca's chief executive, David Brennan, outlined the group's business strategy for Japan at a recent press conference in Osaka. He told reporters: "even in Japan we will seek an opportunity to acquire a small-sized company having a unique technological platform to discover new drugs and promising products, and products themselves, which can assumably strengthen our R&D pipeline, to achieve a sustainable growth in our company although we have no intention to conduct large-scale M&A."
Although Japan only accounts for 6% by region in its global sales, compared with 47% for the USA and 30% for western Europe, the ratio seems to be low compared to the actual pharmaceutical market size in the the other main territories, he noted.
Mainstay drugs still to debut in Japan
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze